To return to the schedule, please click the 'back' button on your web browser.

Safety and Efficacy of Bremelanotide in the RECONNECT Studies
Description: Bremelanotide is a novel melanocortin-4-receptor agonist that is being investigated for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The efficacy and safety of bremelanotide were investigated in two replicate, multicenter, randomized, double-blind, placebo-controlled phase 3 studies (RECONNECT). Compared with placebo, bremelanotide produced clinically meaningful and statistically significant improvements in improving sexual desire and reducing associated distress in premenopausal women after 24 weeks of subcutaneous self-administration on demand prior to sexual activity. No safety issues were identified.
Objective(s): At the conclusion of this workshop, participants will be able to: assess the efficacy and safety profile of bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder.